Pierre Geborek

affiliated with the university
More filtering options
  1. Why do women with early RA respond less well to MTX than men? Gender as a determinant of response in the initial phase of the Swefot trial

    Ronald van Vollenhoven, Sofia Emestam, Lars Coester, Christina Dackhammar, Kristina Forslind, Pierre Geborek, Helena Hellstroem, Lotta Ljung, Rolf Oding, Ingemar Petersson, Annika Teleman, Jan Theander, Ake Thorner, Bo Tornqvist, Eva Waltbrand, Agneta Zickert, Margareta Wornet & Johan Bratt, 2008, In : Scandinavian Journal of Rheumatology. 37, Suppl. 123, p. 52-52

    Research output: Contribution to journalPublished meeting abstract

  2. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)

    Agneta Scheja, Anita Åkesson, Pierre Geborek, Marie Wildt, Claes B Wollheim, Frank Wollheim & Ulrich M Vischer, 2001, In : Arthritis Research & Therapy. 3, 3, p. 178-182

    Research output: Contribution to journalArticle

  3. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases

    S. van Assen, O. Elkayam, N. Agmon-Levin, R. Cervera, M. F. Doran, M. Dougados, P. Emery, Pierre Geborek, J. P. A. Ioannidis, D. R. W. Jayne, C. G. M. Kallenberg, U. Mueller-Ladner, Y. Shoenfeld, L. Stojanovich, G. Valesini, N. M. Wulffraat & M. Bijl, 2011, In : Autoimmunity Reviews. 10, 6, p. 341-352

    Research output: Contribution to journalReview article

  4. Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis.

    Lennart Jacobsson, Carl Turesson, Jan-Åke Nilsson, Ingemar Petersson, Elisabet Lindqvist, Tore Saxne & Pierre Geborek, 2007, In : Annals of the Rheumatic Diseases. 66, 5, p. 670-675

    Research output: Contribution to journalArticle

  5. Treatment with belimumab in SLE does not alter antobody response to 13-valent pneumococcal vaccine

    Johanna Nagel, Tore Saxne, Pierre Geborek, Anders Bengtsson, S Jacobsen, Svaerke Joergensen C, Jan-Åke Nilsson, Lillemor Skattum, Andreas Jönsen & Meliha C Kapetanovic, 2017, In : Lupus. 26, 10, p. 1072-1081

    Research output: Contribution to journalArticle

  6. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

    Johan Askling, C. Michael Fored, Lena Brandt, Eva Baecklund, Lennart Bertilsson, Nils Feltelius, Lars Coster, Pierre Geborek, Lennart Jacobsson, Staffan Lindblad, Jorgen Lysholm, Solbritt Rantapaa-Dahlqvist, Tore Saxne, Ronald F. van Vollenhoven & Lars Klareskog, 2007, In : Annals of the Rheumatic Diseases. 66, 10, p. 1339-1344

    Research output: Contribution to journalArticle

  7. The Swedish biologics register (ARTIS): observations of adverse events when using biologics in clinical practice

    Eva Baecklund, Johan Askling, Lennart Bertilsson, Lars Coster, Nils Feltelius, Michael Fored, Pierre Geborek, Lennart T Jacobsson, Lars Klareskog, Staffan Lindblad, Jorgen Lysholm, Solbrutt Rantapaa-Dahlqvist, Tore Saxne & Ronald van Vollenhoven, 2008, In : Scandinavian Journal of Rheumatology. 37, Suppl. 123, p. 12-12

    Research output: Contribution to journalPublished meeting abstract

  8. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials.

    Lars Erik Kristensen, Ak Jakobsen, Em Bartels, Pierre Geborek, H Bliddal, Tore Saxne, B Danneskiold-Samsøe & R Christensen, 2011, In : Scandinavian Journal of Rheumatology. 40, p. 1-7

    Research output: Contribution to journalArticle

  9. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice

    Ingrid Lekander, Fredrik Borgstrom, Jorgen Lysholm, Ronald F. van Vollenhoven, Staffan Lindblad, Pierre Geborek & Gisela Kobelt, 2013, In : European Journal of Health Economics. 14, 6, p. 863-873

    Research output: Contribution to journalArticle

  10. Ten years with biologics: to whom do data on effectiveness and safety apply?

    Julia F Simard, Elizabeth V Arkema, Anders Sundström, Pierre Geborek, Tore Saxne, Eva Baecklund, Lars Coster, Christina Dackhammar, Lennart Jacobsson, Nils Feltelius, Staffan Lindblad, Solbritt Rantapää-Dahlqvist, Lars Klareskog, Ronald F van Vollenhoven, Martin Neovius & Johan Askling, 2011, In : Rheumatology (Oxford, England). Dec, p. 204-213

    Research output: Contribution to journalArticle

  11. Swedish registers to examine drug safety and clinical issues in RA

    J Askling, CM Fored, Pierre Geborek, LTH Jacobsson, R van Vollenhoven, N Feltelius, S Lindblad & L Klareskog, 2006, In : Annals of the Rheumatic Diseases. 65, 6, p. 707-712

    Research output: Contribution to journalReview article

  12. Studies of mechanisms underlying the prolonged neutrophil survival in ANCA-associated systemic vasculitis

    Mohamed AbdGawad, Lena Gunnarsson, Anders Bengtsson, Pierre Geborek, Mårten Segelmark & Thomas Hellmark, 2009, In : APMIS. 117, p. 125-125

    Research output: Contribution to journalPublished meeting abstract

  13. Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-alpha treatment

    Kaisa Happonen, Tore Saxne, Pierre Geborek, Maria Andersson, Anders Bengtsson, Roger Hesselstrand, Dick Heinegård & Anna Blom, 2012, In : Arthritis Research and Therapy. 14, 1, R15.

    Research output: Contribution to journalArticle

  14. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

    J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, N Feltelus, L Coster, Pierre Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne & L Klareskog, 2005, In : Annals of the Rheumatic Diseases. 64, 10, p. 1421-1426

    Research output: Contribution to journalArticle

  15. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

    J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, L Coster, Pierre Geborek, Lennart Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne, V Romanus, L Klareskog & N Feltelius, 2005, In : Arthritis and Rheumatism. 52, 7, p. 1986-1992

    Research output: Contribution to journalArticle

  16. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

    N Feltelius, CM Fored, P Blomqvist, L Bertilsson, Pierre Geborek, Lennart Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne & L Klareskog, 2005, In : Annals of the Rheumatic Diseases. 64, 2, p. 246-252

    Research output: Contribution to journalArticle

  17. Prevention of joint destruction in antigen-induced arthritis

    Frank Wollheim, Hans Telhag, Anders Henricsson & Pierre Geborek, 1994, In : Clinical Immunology and Immunopathology. 70, 1, p. 19-21

    Research output: Contribution to journalArticle

  18. Prevalence of spondyloarthritis and its subtypes in southern Sweden

    Emma Haglund, Ann Bremander, Ingemar Petersson, Britta Strömbeck, Stefan Bergman, Lennart Jacobsson, Aleksandra Turkiewicz, Pierre Geborek & Martin Englund, 2011, In : Annals of the Rheumatic Diseases. 70, p. 943-948

    Research output: Contribution to journalArticle

  19. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

    Karen Hambardzumyan, Rebecca Bolce, Saedis Saevarsdottir, Scott E Cruickshank, Eric H Sasso, David Chernoff, Kristina Forslind, Ingemar Petersson, Pierre Geborek & Ronald F van Vollenhoven, 2015, In : Annals of the Rheumatic Diseases. 74, 6, p. 1102-1109

    Research output: Contribution to journalArticle

Previous 1 2 3 Next